Media Room
First quarter 2026
Q1 2026 results will be reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation will be followed by a Q&A session.
Press Releases
April 7, 2026
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
March 31, 2026
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
March 28, 2026
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
October 2025
Annual Report on Form 20-F
Annual Report on Form 20-F 2025
July 2025
Half-year Financial Reports
Half Year 2025 Financial Report
July 2025
Half-year Financial Reports
Half year 2025 financial report XBRL package
September 2024
Annual Report on Form 20-F
Annual Report on Form 20-F 2024